Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the ...
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass., April 23, 2024 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine …